Second-line TB drugs: ‘It is more difficult to assess adverse effects in children’
Prof. H. Simon Schaaf, a clinical researcher from the Department of Paediatrics and Child Health, Faculty of Health Sciences,
Read MoreProf. H. Simon Schaaf, a clinical researcher from the Department of Paediatrics and Child Health, Faculty of Health Sciences,
Read MoreDr. Peter R. Donald, Emeritus Professor in the Department of Paediatrics and Child Health of the Faculty of Health
Read More“The ultimate goal of evidence-based drug treatment is to produce a desired pharmacological response in a predictable manner and also
Read MoreMercedes C Becerra is an Associate Professor in the Department of Global Health and Social Medicine at Harvard Medical School.
Read MoreThe Sentinel Project on Pediatric Drug-Resistant Tuberculosis is a collective power of a global partnership by experts and others
Read MoreProf. H. Simon Schaaf, a clinical researcher from the Department of Paediatrics and Child Health, Faculty of Health Sciences,
Read More“A child with TB [is] as likely as an adult with TB to have MDR-TB [multi-drug resistant TB],” notes
Read MoreProf Peter R. Donald, Emeritus Professor in the Department of Paediatrics and Child Health of the Faculty of Health Sciences
Read MoreWith 8.6 million people across the world developing tuberculosis in 2012 and nearly 1.3 million succumbing to the disease, and
Read MoreAlthough tuberculosis killed 1.3 million people across the globe in 2012 and nearly 8.6 million developed the disease, the world
Read More“Measurement is the first step that leads to control and eventually to improvement. If you can’t measure something, you can’t
Read MoreUnlike adults, children under five years of age are particularly vulnerable to getting infected with TB and may develop the
Read MoreOf the nine million cases of tuberculosis (TB) across the world annually, children below 15 years of age account
Read More